pharma · Breast Cancer · Lumbosacral Radicular Pain · SMNR
Semnur Pharmaceuticals
Semnur Pharmaceuticals patent portfolio — 8 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2013
- Employees
- 9
- Programs
- 2
- Drugs
- 2
- Patents
- 8
Semnur Pharmaceuticals patents
8 pharmaceutical patents indexed for Semnur Pharmaceuticals. 0 expire within 24 months.
Semnur Pharmaceuticals has 8 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12285485
Methods of treating pain
granted -
US 12016867
Methods of treating inflammation and/or pain
granted -
US 11364251
Pharmaceutical formulation
granted -
US 11020485
Pharmaceutical formulation
granted -
US 10744144
Pharmaceutical formulation
granted -
US 10500284
Pharmaceutical formulation
granted -
US 10117938
Pharmaceutical formulation
granted -
US 9833460
Pharmaceutical formulation
granted
Frequently asked questions
How many patents does Semnur Pharmaceuticals have?
8 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Semnur Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.